专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150283178A1 TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR 审中-公开
标题翻译：使用抗CD19基因抗原受体治疗癌症
公开(公告)号：US20150283178A1
公开(公告)日：2015-10-08
申请号：US14680860
申请日：2015-04-07
申请人： Carl H. June , David L. Porter , Marcela Maus , Mariusz Wasik , Saar Gill , Joseph Fraietta , Marco Ruella , John Byrd , Jason Dubovsky , Amy Johnson , Natarajan Muthusamy , Saad Kenderian , Joan Mannick , David Glass , Leon Murphy , Jennifer Brogdon , William Raj Sellers
发明人： Carl H. June , David L. Porter , Marcela Maus , Mariusz Wasik , Saar Gill , Joseph Fraietta , Marco Ruella , John Byrd , Jason Dubovsky , Amy Johnson , Natarajan Muthusamy , Saad Kenderian , Joan Mannick , David Glass , Leon Murphy , Jennifer Brogdon , William Raj Sellers
IPC分类号： A61K35/17 , A61K31/519 , C07K16/30 , A61K31/53 , C07K14/725 , C07K16/28 , A61K31/436 , A61K39/395 , A61K45/06
CPC分类号： A61K35/17 , A61K31/436 , A61K31/519 , A61K31/53 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K14/7051 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/03 , C12N5/0636 , C12N2501/599 , C12N2501/727 , C12N2510/00 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
摘要翻译：本发明提供了用于治疗与CD19表达相关的疾病的组合物和方法，例如通过如本文所述施用包含本文所述的CD19 CAR的重组T细胞与激酶抑制剂，例如本文所述的激酶抑制剂组合。本发明还提供了本文所述的试剂盒和组合物。

2. 发明申请

US20180140602A1 COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES 审中-公开
公开(公告)号：US20180140602A1
公开(公告)日：2018-05-24
申请号：US15564463
申请日：2016-04-07
申请人： Daniela Angst , John Byrd , Jason Dubovsky , Joseph A. Fraietta , Francois Gessier , Saar Gill , Amy Johnson , Carl H. June , Marcela Maus , Natarajan Muthusamy , David L. Porter , Marco Ruella , Anna Vulpetti , Mariusz Wasik , Novartis AG , The Trustees of the University of Pennsylvania
发明人： Daniela Angst , John Byrd , Jason Dubovsky , Joseph A. Fraietta , Francois Gessier , Saar Gill , Amy Johnson , Carl H. June , Marcela Maus , Natarajan Muthusamy , David L. Porter , Marco Ruella , Anna Vulpetti , Mariusz Wasik
IPC分类号： A61K31/505 , A61K35/17 , C07K16/28 , A61K31/506 , C07K16/30 , A61P35/00 , A61P35/02
CPC分类号： A61K31/505 , A61K31/506 , A61K35/17 , A61K45/06 , A61K2035/124 , A61K2039/505 , A61K2039/545 , A61P35/00 , A61P35/02 , C07K16/2803 , C07K16/30 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N5/0636 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.

3. 发明授权

US09815901B2 Treatment of cancer using a CD123 chimeric antigen receptor 有权
公开(公告)号：US09815901B2
公开(公告)日：2017-11-14
申请号：US14830392
申请日：2015-08-19
申请人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
发明人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , C12N5/078 , C12N5/0783 , A61K39/00 , C07K16/24
CPC分类号： C07K16/2866 , A61K39/0011 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , C07K16/244 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/03 , C07K2319/33 , C12N5/0636
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

4. 发明申请

US20160068601A1 TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR 有权
标题翻译：治疗癌症使用CD123基因抗原受体
公开(公告)号：US20160068601A1
公开(公告)日：2016-03-10
申请号：US14830392
申请日：2015-08-19
申请人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
发明人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , A61K45/06 , A61K39/00
CPC分类号： C07K16/2866 , A61K39/0011 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , C07K16/244 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/03 , C07K2319/33 , C12N5/0636
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
摘要翻译：本发明提供用于治疗与CD123表达相关的疾病的组合物和方法。本发明还涉及对CD123特异性的嵌合抗原受体（CAR），编码它的载体和包含CD123 CAR的重组细胞。本发明还包括施用表达包含CD123结合结构域的CAR的遗传修饰的细胞的方法。

5. 发明授权

US09499629B2 Use of chimeric antigen receptor-modified T-cells to treat cancer 有权
标题翻译：使用嵌合抗原受体修饰的T细胞治疗癌症
公开(公告)号：US09499629B2
公开(公告)日：2016-11-22
申请号：US13992622
申请日：2011-12-09
申请人： Carl H. June , Bruce L. Levine , David L. Porter , Michael D. Kalos , Michael C. Milone
发明人： Carl H. June , Bruce L. Levine , David L. Porter , Michael D. Kalos , Michael C. Milone
IPC分类号： C12N5/071 , C12N5/0783 , C12N5/22 , C07K16/28 , A61K35/17 , A61K39/00 , A61K39/395 , C12N15/85 , C07K14/705 , A61K48/00 , C07K14/525 , C07K14/725 , C07K16/30 , C12N7/00 , A61K38/17 , A61K45/06
CPC分类号： C12N5/0636 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/585 , C07K14/075 , C07K14/525 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/53 , C07K2317/622 , C07K2317/76 , C07K2317/80 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/74 , C12N7/00 , C12N15/85 , C12N15/861 , C12N2501/51 , C12N2501/515 , C12N2510/00 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , A61K2300/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
摘要翻译：本发明提供了治疗人类癌症的组合物和方法。本发明涉及施用经遗传修饰的T细胞以表达CAR，其中CAR包含抗原结合结构域，跨膜结构域，共刺激信号传导区和CD3ζ信号结构域。

6. 发明申请

US20130287748A1 Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer 有权
标题翻译：使用嵌合抗原受体修饰的T细胞治疗癌症
公开(公告)号：US20130287748A1
公开(公告)日：2013-10-31
申请号：US13992622
申请日：2011-12-09
申请人： Carl H. June , Bruce L. Levine , David L. Porter , Michael D. Kalos , Michael C. Milone
发明人： Carl H. June , Bruce L. Levine , David L. Porter , Michael D. Kalos , Michael C. Milone
IPC分类号： A61K35/14
CPC分类号： C12N5/0636 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/585 , C07K14/075 , C07K14/525 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/53 , C07K2317/622 , C07K2317/76 , C07K2317/80 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/74 , C12N7/00 , C12N15/85 , C12N15/861 , C12N2501/51 , C12N2501/515 , C12N2510/00 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , A61K2300/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
摘要翻译：本发明提供了治疗人类癌症的组合物和方法。本发明涉及施用经遗传修饰的T细胞以表达CAR，其中CAR包含抗原结合结构域，跨膜结构域，共刺激信号传导区和CD3ζ信号结构域。

7. 发明申请

US20210177896A1 THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELLS 有权
公开(公告)号：US20210177896A1
公开(公告)日：2021-06-17
申请号：US16305728
申请日：2017-06-02
申请人： David L. Porter , Noelle Frey , Carl H. June , Simon Lacey , Fang Chen , Jan J. Melenhorst , Tetiana Taran , Karen Thudium Mueller , Patricia Wood , Yiyun Zhang , Novartis AG , The Trustees of the University of Pennsylvania
发明人： David L. Porter , Noelle Frey , Carl H. June , Simon Lacey , Fang Chen , Jan J. Melenhorst , Tetiana Taran , Karen Thudium Mueller , Patricia Wood , Yiyun Zhang
IPC分类号： A61K35/17 , A61P35/00 , C07K14/705 , G01N33/50 , G01N33/68 , C07K16/28
摘要： The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.

8. 发明授权

US4907553A Speed control cable attachment 失效
标题翻译：速度控制电缆附件
公开(公告)号：US4907553A
公开(公告)日：1990-03-13
申请号：US288595
申请日：1988-12-22
申请人： David L. Porter
发明人： David L. Porter
IPC分类号： B60K28/16 , B60K31/02 , F02D9/02 , F02D11/02 , F02D11/10 , F16C1/18
CPC分类号： F02D11/02 , B60K28/16 , B60K31/02 , F16C1/18 , F02D2009/0254 , F02D2011/103
摘要： A cable attachment assembly for coupling and uncoupling a cable to a throttle control system partially encased within a housing. The housing includes an opening aligned with a cable drum and a protrusion adjacent the opening. A cable cover assembly includes an integrally formed collar having a resilient member formed thereon with a first flap at its end. A second flap is integrally formed on the collar adjacent the first flap. During rotation in an assembly process, the resilient member is compressed as the first flap rotates along the protrusion. As the first flap passes the protrusion, the resilient member is outwardly deflected thereby locking the protrusion between the first and second flaps and, accordingly, locking the cable cover assembly to the housing.

9. 发明授权

US4320748A Fracture brace 失效
标题翻译：骨折支架
公开(公告)号：US4320748A
公开(公告)日：1982-03-23
申请号：US208504
申请日：1980-11-20
申请人： Walter L. Racette , David L. Porter
发明人： Walter L. Racette , David L. Porter
IPC分类号： A61F5/01 , A61F5/058 , A61F3/00
CPC分类号： A61F5/0127 , A61F5/0585 , Y10S128/15
摘要： A fracture brace for a leg has an interior jacket for placement over the front of a leg, and for wrapping around the medial and lateral sides of a leg outside of a posterior shell. The posterior shell fits over the calf and the lateral and medial sides of the leg. Straps anchored on the shell unite the jacket and the shell to form an enveloping case for the leg that permits transmission of bearing pressures through the fleshy part of the leg, the tibia, and the brace. An interior pad integral with the jacket extends along the anterior of a leg from the proximal tibia to the distal tibia. There the pad wraps to the sides to provide padding for the bony prominences of the medial and lateral malleolus. A footplate connects to the jacket through a pair of uprights, each of which attaches to the footplate through a pivot and to the jacket by hook and pile fasteners. The attachment to the jacket permits adjustment of the footplate with respect to the jacket and therefore the foot with respect to the tibia: (1) in translation generally along the axis of the tibia, (2) in translation generally along an axis through the length of the foot, (3) in rotation generally around the axis of the tibia, and (4) in rotation generally about the axis through the length of the foot. The footplate can rotate about axes generally medial-to-lateral and through pivots connecting the footplate and the uprights.
摘要翻译：用于腿部的骨折支架具有用于放置在腿的前部上的内部护套，并且用于围绕后壳外侧的腿的内侧和外侧缠绕。后壳适合小腿和腿的外侧和内侧。锚固在壳上的皮带将护套和外壳结合在一起，以形成用于腿部的包封壳，其允许轴承压力通过腿，胫骨和支架的肉质部分传递。与护套一体的内部衬垫沿着腿部的前部从胫骨近端延伸到远端胫骨。那里的垫子包裹在侧面，为内侧和外侧的踝骨的骨骼突起提供衬垫。一个脚板通过一对立柱连接到护套，每个立柱通过枢轴连接到脚踏板，并通过钩和紧固件连接到护套。与护套的连接允许相对于护套调节脚板，因此相对于胫骨调节脚部：（1）大致沿着胫骨的轴线平移，（2）通常沿着穿过长度的轴线平移（3）通常围绕胫骨的轴线旋转，以及（4）通常围绕通过脚的长度的轴线旋转。脚踏板可以围绕轴线大致内侧和外侧旋转，并通过连接底板和立柱的枢轴旋转。

10. 发明申请

US20090090794A1 LOW PRESSURE FUEL INJECTOR 审中-公开
标题翻译：低压燃油喷射器
公开(公告)号：US20090090794A1
公开(公告)日：2009-04-09
申请号：US11867393
申请日：2007-10-04
申请人： David Ling-Shun Hung , Vivek A. Jairazbhoy , David L. Porter
发明人： David Ling-Shun Hung , Vivek A. Jairazbhoy , David L. Porter
IPC分类号： F02M69/04
CPC分类号： F02M61/1853 , F02M61/18 , F02M61/1806 , F02M61/188
摘要： A low pressure fuel injector capable of atomizing fuel at relatively low pressure is configured to have reduced hydraulic resistance. Reduction in the hydraulic resistance minimizes the pressure drop within the fuel injector and thereby improves atomization of the fuel for improved fuel economy and performance, and decreased emissions.
摘要翻译：能够在相当低的压力下雾化燃料的低压燃料喷射器被配置为具有降低的液压阻力。降低液压阻力使燃料喷射器内的压降最小化，从而改善燃料雾化，提高燃油经济性和性能，减少排放。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式